Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $159.69 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$159.69 USD
+0.16 (0.10%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $159.69 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
Zacks News
Bruker (BRKR) Q2 Earnings and Revenues Top, '23 Sales View Up
by Zacks Equity Research
Bruker (BRKR) delivers better-than-expected earnings and revenues in the second quarter of 2023.
Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised
by Zacks Equity Research
Intra-Cellular (ITCI) reports better-than-expected second-quarter results. Caplyta sales continue to drive growth. The company raises its financial outlook for full-year Caplyta sales.
The Zacks Analyst Blog Highlights Johnson & Johnson, General Dynamics, Pioneer Natural Resources, Alibaba Group and Autodesk
by Zacks Equity Research
Johnson & Johnson, General Dynamics, Pioneer Natural Resources, Alibaba Group and Autodesk are part of the Zacks top Analyst Blog.
Looking to Bet On Perfect AAA Credit Ratings? Play These ETFs
by Sanghamitra Saha
In light of Fitch Ratings' downgrade of U.S. credit, investors might be interested in identifying companies and countries that still hold the desirable 'AAA' credit rating.
Q2 Earnings Season Scorecard and Research Reports for JNJ, Pioneer Natural & Others
by Sheraz Mian
Today's Research Daily features a real-time Q2 scorecard and updated reports on JNJ (JNJ), General Dynamics (GD), Pioneer Natural Resources (PXD) and others.
Editas' (EDIT) Q2 Earnings Beat, Sales Miss, Pipeline in Focus
by Zacks Equity Research
Editas (EDIT) reports mixed second-quarter 2023 results. EDIT-301 studies remain on track to provide updates by the end of the year. The stock of the company rises about 6% on Wednesday.
Sarepta (SRPT) Q2 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Sarepta's (SRPT) second-quarter 2023 earnings beat estimates. Though total revenues register strong year-over-year growth during the quarter, the same misses the mark.
Allogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) second-quarter results beat estimates for earnings but misses the mark on sales. Management reiterated its previously-issued financial guidance for 2023.
Moderna (MRNA) Beats on Q2 Earnings & Sales, Raises '23 View
by Zacks Equity Research
Moderna (MRNA) beats expectations for earnings and sales. Management raises its product revenue guidance based on potential U.S. demand for COVID vaccines during the upcoming fall season.
Acadia (ACAD) Q2 Earnings & Revenues Beat Estimates, '23 View Up
by Zacks Equity Research
Acadia (ACAD) reports better-than-expected second-quarter 2023 results, raising its financial guidance for the year. The company also provides updates on its pipeline.
Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated
by Zacks Equity Research
Pacira (PCRX) announces weaker-than-expected second-quarter 2023 results. The company updates its 2023 financial guidance.
Blueprint (BPMC) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Blueprint (BPMC) reports better-than-expected second-quarter 2023 results, driven by increased Ayvakit sales, following FDA approval in a new indication.
United Therapeutics (UTHR) Q2 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) second-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
Vertex (VRTX) Beats on Q2 Earnings & Sales, Raises '23 View
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) second-quarter 2023 earnings and sales beat estimates. Based on strong Trikafta uptake, management raises its financial guidance for 2023.
Merck (MRK) Beats on Q2 Earnings and Sales, Ups 2023 View
by Zacks Equity Research
Merck (MRK) beats Q2 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.
Apellis (APLS) Q2 Earnings Top, Syfovre Sales Boost Revenues
by Zacks Equity Research
Apellis (APLS) reports better-than-expected second-quarter 2023 results. However, the stock falls 20% due to ambiguity surrounding Syfovre's safety profile.
Company News for Aug 1, 2023
by Zacks Equity Research
Companies in The News Are: XOM, JNJ, ON, NFLX
Forget Soft Landing for Economy, Think About a New Takeoff
by Nalak Das
At this stage, we have narrowed our search to five stocks. These are: META, GOOGL, KO, PEP, JNJ.
These 3 Quarterly Releases Positively Shocked the Market
by Derek Lewis
There have been several notable surprises throughout the Q2 earnings season so far, including those from these three companies.
AstraZeneca (AZN) Q2 Earnings & Sales Beat, Nil COVID Sales
by Zacks Equity Research
AstraZeneca (AZN) beats second-quarter estimates for earnings and sales. The company did not generate any revenues from COVID-19 medications. Management reaffirms its 2023 guidance.
Dorian and Oxford Industries have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Dorian and Oxford Industries are part of the Zacks Bull and Bear of the Day article.
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises '23 View
by Zacks Equity Research
AbbVie's (ABBV) second-quarter 2023 earnings and sales beat estimates. The company raises its EPS guidance. Stock rises post the announcement.
Alkermes (ALKS) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) reports encouraging second-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.
Fed's July Rate Hike and Comments Match Expectations: 5 Picks
by Nalak Das
We have narrowed our search to five U.S. corporate behemoths. These are: META, GOOGL, ISRG, JNJ, PEP.
3 Top Blue Chip Stocks to Ride the Dow Rally
by Tirthankar Chakraborty
As the Dow continues to scale upward, it's prudent to invest in stocks such as JPMorgan (JPM), Walmart (WMT) and Johnson & Johnson (JNJ) that are listed on the said index and are financially sound.